

GvHGvL 2020

Regensburg, Germany

Location: University Hospital Regensburg

March 4-6, 2020

Wednesday March 4:

13:00 Welcome

13:15 -14:50 Session I

Pathophysiology - new aspects:

Chairs: M Edinger, M v d Brink

13:15 – 13:40 IL22 and intestinal stem cells: AM Hanash, New York

13:40 – 14:05 Tissue tolerance: P Reddy, Ann Arbor

14:05 – 14:30 CNS as a target of GvHD: R Zeiser, Freiburg

14:30 – 14:50 Sting/IFN signaling and microbiota: H Poeck, Regensburg

14:50 – 15:20 Kaffeepause

15:20-17:00 Session II

Biomarkers:

Chairs: E Holler, S Paczesny

15:20 – 15:45 Update on MAGIC: J Levine, New York

15:45 – 16:10 Integrating endothelial damage: T Luft, Heidelberg

16:10 – 16:35 Unbiased Metabolomics: G Socie, Paris

16:35 – 17:00 T reg repertoire: C Koenecke, Hannover

17:00 – 18:00 HJ Kolb Award and lecture

18:30-20:00 Evening discussion

Thursday, March 5:

8:30 – 10:10 Session III

Prophylaxis and treatment:

Chairs: R Zeiser, N Kröger

08:30 – 08:55 Indoles: E Waller, Atlanta

08:55 – 09:20 PostTx Cy in MUD and MRD: A Bacigalupo, Rome

09:20 – 09:45 FMT and beyond: F Malard, Paris

09:45 – 10:10 Outpatient allogeneic SCT – rationale and first experiences: N Chao, Durham

10:10 – 10:40 Kaffeepause

10:40 – 11:30: Keynote lecture

Chairs: A Beilhack, M Edinger:

Regulatory T cells in allogeneic SCT – R Negrin, Stanford

11:30 - 12:45 cGvHD

Chairs: D Wolff, H Greinix

11:30 – 11:55 Peripheral antigen display and autoimmunity in GVHD: R Chakraverty, London

11:55 – 12:20 Drug targetable biomarkers of chronic GvHD: S Paczesny, Indianapolis

12:20 – 12:45 Low dose IL2 in cGvHD: J Koreth, Boston

12:45 – 14:00 Mittagspause

14:00 - 15:15 Immunoreconstitution

Chairs: P Hoffmann, M Feuerer

14:00 – 14:25: New aspects on IgA in allogeneic SCT: T Winkler, Erlangen

14:25 – 14:50: Enhancing thymic recovery: E Velardi, Rome

14:50 – 15:15: Endothelial cells in thymic regeneration: T Wertheimer, Regensburg

15:15.-16:00 Kaffeepause

16:00– 17:15: GvL I

Chairs: P Beckhove, A Mackensen

16:00 - 16:25: Novel hemibodies for personalized GvL Therapy: G Stuhler, Würzburg

16:25 - 16:50: DP specific strategies: K Fleischhauer, Essen

16:50 – 17:15: Regulation of class II in relapse: A Kremer, Erlangen

19:00 Social dinner

Friday March 6:

9:00 – 09:45 Keynote lecture

Chairs S Thomas, HJ Kolb

The role of CAR T cells in the setting of allogeneic SCT: M v d Brink, New York

9:45 – 10:55 GvL II

Chairs W Herr, H Einsele

09:40 – 10:05 Immune signature drives leukemia escape after aHSCT: L. Vago, Milano

10:05- 10:30 Bone marrow T cell exhaustion and relapse: C Bonini, Milano

10:30 – 10:55 mutNPM1 –specific TCR in AML: Marieke Griffioen, Leiden

10:55 – 11:30 Kaffeepause

11:30 – 13:10 GvL III

Chairs W Herr, H Einsele

11:30 – 11:55 Genome edited allo-CART: G Lucchini, London

11:55 – 12:20 Novel targets for CAR T cells in myeloma and AML: M Hudecek, Würzburg

12:20 – 12: 45 Enhancing CAR-T cells: H Abken, Regensburg

12:45 – 13:10 CART and memory T stem cells – L Gattinoni, Regensburg

13:10-13:30: Closure and farewell